{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:34Z","timestamp":1767134674974,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd001912.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000}}],"reference-count":48,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001912.pub5","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T15:47:20Z","timestamp":1601480840000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prophylactic anti-staphylococcal antibiotics for cystic fibrosis"],"prefix":"10.1002","volume":"2020","author":[{"given":"Margaret","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; University of Washington School of Medicine; Seattle Washington USA"},{"name":"University of Washington School of Public Health; Seattle USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oli","family":"Rayner","sequence":"additional","affiliation":[{"name":"Plymouth UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R","family":"Smyth","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG); School of Medicine, University of Nottingham; Nottingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"issue":"1 Spec No","key":"10.1002\/14651858.CD001912.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/adc.66.1_Spec_No.29","article-title":"Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening","volume":"66","author":"Chatfield","year":"1991","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0002|cit2","unstructured":"Owen G West J Maguire S Ryley H Goodchild M Weller PH Continuous and intermittent antibiotic therapy in cystic fibrosis patients to age 4 years [abstract] Proceedings of the 17th European Cystic Fibrosis Conference; 1991 June 18-21; Copenhagen, Denmark 1991 95"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0003|cit3","first-page":"222","article-title":"Longitudinal relationship between clinical status, lung infection and immune responses in young cystic fibrosis patients [abstract]","volume":"Suppl 5","author":"West","year":"1990","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0004|cit4","first-page":"G(b)3","article-title":"Screening for cystic fibrosis in Wales and the West Midlands 2: Clinical evaluation [abstract]","volume":"74","author":"Williams","year":"1988","journal-title":"Excerpta Medica, Asia Pacific Congress Series"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0005|cit5","unstructured":"Schlesinger E Muller W von der Hardt H Schirg E Rieger CHL Effect of long-term continuous anti-staphylococcal antibiotic treatment in young children with cystic fibrosis [abstract] Proceedings of the 9th International Cystic Fibrosis Congress 1984 4.14"},{"issue":"3","key":"10.1002\/14651858.CD001912.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: A randomised controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0007|cit7","unstructured":"Stutman HR Marks MI Cephalexin prophylaxis in newly diagnosed infants with cystic fibrosis [abstract] Proceedings of the 6th Annual North American Cystic Fibrosis Conference; 1992 1992 147 8"},{"issue":"2","key":"10.1002\/14651858.CD001912.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/adc.71.2.133","article-title":"Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment","volume":"71","author":"Beardsmore","year":"1994","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0009|cit9","unstructured":"Weaver LT Green MR Nicholson K Heeley AF Mills J Kuzemko JA Continuous prophylactic flucloxacillin improves outcome of infants with cystic fibrosis (CF) detected soon after birth [abstract] Proceedings of 63rd Annual Meeting of the British Paediatric Association; 1991; Warwick 1991 24"},{"issue":"2","key":"10.1002\/14651858.CD001912.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/adc.70.2.84","article-title":"Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period","volume":"70","author":"Weaver","year":"1994","journal-title":"Archives of Disease in Childhood"},{"issue":"12","key":"10.1002\/14651858.CD001912.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/BF01961145","article-title":"Susceptibility to various anti-microbial agents of Staphylococcus aureus isolates from cystic fibrosis patients","volume":"11","author":"Ballestero","year":"1992","journal-title":"European Journal of Clinical Microbiology & Infectious Diseases"},{"issue":"3","key":"10.1002\/14651858.CD001912.pub5-BIB0012|cit12","first-page":"207","article-title":"Efficacy of antimicrobial drugs against staphylococci in cystic fibrosis","volume":"16","author":"Brown","year":"1980","journal-title":"Australian Paediatric Journal"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0013|cit13","unstructured":"Denning CR Park S Grece CA Mellin GW Continuous versus intermittent oral antibiotics in the management of patients with cystic fibrosis [abstract] 18th Annual Meeting Cystic Fibrosis Club Abstracts 1977 23"},{"issue":"138","key":"10.1002\/14651858.CD001912.pub5-BIB0014|cit14","first-page":"111","article-title":"Fusidic acid in cystic fibrosis","volume":"29","author":"Feigelson","year":"1993","journal-title":"Pediatre"},{"issue":"1","key":"10.1002\/14651858.CD001912.pub5-BIB0015|cit15","first-page":"7","article-title":"A multicentric comparison of related pharmacologic features of cephalexin and dicloxacillin given for two months to young children with cystic fibrosis","volume":"5","author":"Harrison","year":"1985","journal-title":"Pediatric Pharmacology"},{"issue":"Suppl B","key":"10.1002\/14651858.CD001912.pub5-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/25.suppl_B.45","article-title":"Clinical experiences with fusidic acid in cystic fibrosis patients","volume":"25","author":"Jensen","year":"1990","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"10.1002\/14651858.CD001912.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/AAC.01797-10","article-title":"Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis","volume":"55","author":"Keel","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001912.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"S22, Abstract n","DOI":"10.1016\/S1569-1993(10)60085-9","article-title":"In-vivo data support equivalent therapeutic efficacy of a new tobramycin inhalation solution (150mg\/1.5ml) administered by the eFlow\u00ae electronic nebuliser compared to TOBI\u00ae in the PARI LC PLUS\u00ae [abstract]","volume":"9","author":"Keller","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0019|cit19","first-page":"273","volume-title":"CF: horizons","author":"Kerrebijn","year":"1984"},{"issue":"4","key":"10.1002\/14651858.CD001912.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0022-3476(79)80785-4","article-title":"A placebo controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis","volume":"95","author":"Loening-Baucke","year":"1979","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0021|cit21","unstructured":"Loening-Baucke V Mischler EH Myers MG Cephalexin compared to placebo in the management of patients with cystic fibrosis [abstract] 19th Annual Meeting Cystic Fibrosis Club Abstracts 1978 69"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD001912.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1203\/00006450-197804001-00795","article-title":"Cephalexin in cystic fibrosis: a placebo-controlled study [abstract]","volume":"12","author":"Loening-Baucke","year":"1978","journal-title":"Pediatric Research"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0023|cit23","unstructured":"Epidemiology and treatment of small-colony variant Staphylococcus aureus in cystic fibrosis www.clinicaltrials.gov\/ct2\/show\/NCT02547116"},{"issue":"4","key":"10.1002\/14651858.CD001912.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3476(82)80726-9","article-title":"Antibiotic prophylaxis in cystic fibrosis: inhaled cephaloridine as an adjunct to oral cloxacillin","volume":"101","author":"Nolan","year":"1982","journal-title":"Journal of Pediatrics"},{"issue":"4","key":"10.1002\/14651858.CD001912.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0022-3476(81)80282-X","article-title":"Clindamycin therapy of staphylococcal pulmonary infections in patients with cystic fibrosis","volume":"99","author":"Shapera","year":"1981","journal-title":"Journal of Pediatrics"},{"issue":"5","key":"10.1002\/14651858.CD001912.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1651-2227.1982.tb09526.x","article-title":"Antibiotic treatment of staphylococcus aureus infection in cystic fibrosis","volume":"71","author":"Szaff","year":"1982","journal-title":"Acta Paediatrica Scandinavica"},{"issue":"7636","key":"10.1002\/14651858.CD001912.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(70)90523-4","article-title":"Fusidic acid and lincomycin therapy in staphylococcal infections in cystic fibrosis","volume":"1","author":"Wright","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0028|cit28","unstructured":"CF START www.clinicaltrialsregister.eu\/ctr-search\/search?query=2016-002578-11 2016"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0029|cit29","unstructured":"A trial to determine the safest and most effective antibiotic strategy for infants diagnosed with CF www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-002578-11-GB"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0030|cit30","unstructured":"CF START: a national UK trial to determine whether taking an antibiotic (flucloxacillin) every day predisposes infants with cystic fibrosis (CF) to earlier infection with a bug, Pseudomonas aeruginosa, that is resistant to treatment www.who.int\/trialsearch\/Trial2.aspx?TrialID=ISRCTN18130649"},{"issue":"6994","key":"10.1002\/14651858.CD001912.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1136\/bmj.310.6994.1571","article-title":"Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis","volume":"310","author":"Armstrong","year":"1995","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD001912.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K","article-title":"Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis","volume":"21","author":"Armstrong","year":"1996","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD001912.pub5-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"P24","DOI":"10.1136\/archdischild-2016-311535.33","article-title":"Children with cystic fibrosis: understanding issues related to oral administration of liquid flucloxacillin","volume":"101","author":"Batchelor","year":"2015","journal-title":"Archives of Disease in Childhood"},{"issue":"2","key":"10.1002\/14651858.CD001912.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1136\/adc.71.2.133","article-title":"Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment","volume":"71","author":"Beardsmore","year":"1994","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01314939","article-title":"The systematic evaluation of the chest radiograph in cystic fibrosis","volume":"2","author":"Chrispin","year":"1974","journal-title":"Pediatric Radiology"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0036|cit36","unstructured":"Higggins JPT Altman DG on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"18","key":"10.1002\/14651858.CD001912.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM199204303261804","article-title":"Prediction of mortality in patients with cystic fibrosis","volume":"326","author":"Kerem","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD001912.pub5-BIB0038|cit38","first-page":"725-34","article-title":"Changes in the normal maximal expiratory flow-volume curve with growth and aging","volume":"127","author":"Knudson","year":"1983","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/thx.54.5.380","article-title":"Systematic review of antistaphyloccal antibiotic therapy in cystic fibrosis.","volume":"54","author":"McCaffery","year":"1999","journal-title":"Thorax"},{"issue":"9263","key":"10.1002\/14651858.CD001912.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials","volume":"357","author":"Moher","year":"2001","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD001912.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/adc.77.6.497","article-title":"Height and weight in cystic fibrosis: a cross sectional survey","volume":"77","author":"Morison","year":"1997","journal-title":"Archives of Disease in Childhood"},{"issue":"1","key":"10.1002\/14651858.CD001912.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1164\/rccm.201011-1892OC","article-title":"Infection, inflammation, and lung function decline in infants with cystic fibrosis","volume":"184","author":"Pillarisetti","year":"2011","journal-title":"American Journal of Respiratory & Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD001912.pub5-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/ijpp.12308","article-title":"A mixed methods study of the administration of flucloxacillin oral liquid; identifying strategies to overcome administration issues of medicines with poor palatability","volume":"25","author":"Rouse","year":"2016","journal-title":"International Journal of Pharmacy Practice"},{"key":"10.1002\/14651858.CD001912.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1001\/archpedi.1958.02060060008002","article-title":"Long term study of one hundred five patients with cystic fibrosis","volume":"96","author":"Shwachman","year":"1958","journal-title":"American Journal of Diseases of Children"},{"issue":"7204","key":"10.1002\/14651858.CD001912.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/bmj.319.7204.257a","article-title":"Many reports of RCTs give insufficient data for Cochrane reviewers","volume":"319","author":"Walters","year":"1999","journal-title":"BMJ"},{"issue":"3","key":"10.1002\/14651858.CD001912.pub5-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD001912.pub5-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub3","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD001912.pub5-BIB0048|cit48","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub4","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Smyth","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T04:48:00Z","timestamp":1631249280000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001912.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":48,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001912.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}